The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 28, 2023

Filed:

May. 20, 2022
Applicants:

Merck Sharp & Dohme Llc, Rahway, NJ (US);

Werthenstein Biopharma Gmbh, Lucerne, CH;

Inventors:

Stephen M. Dalby, Springfield Township, NJ (US);

Clinton Scott Shultz, Maplewood, NJ (US);

Chintal Desai, Flemington, NJ (US);

Joshua Lee, Parlin, NJ (US);

Zhiwei Chen, Clark, NJ (US);

Jungchul Kim, Basking Ridge, NJ (US);

Nastaran Salehi Marzijarani, Mahwah, NJ (US);

Tao Wang, Cranford, NJ (US);

Eric M. Phillips, Jersey City, NJ (US);

Patrick Larpent, Luzem, CH;

Het P. Patel, Groton, CT (US);

Haiheng Guo, Shanghai, CN;

Xin Wang, Shanghai, CN;

Kangze Dai, Shanghai, CN;

Lu Chen, Shanghai, CN;

Teng Li, Shanghai, CN;

Taotao Lu, Shanghai, CN;

Jianjun Duan, Shanghai, CN;

Assignees:

Merck Sharp & Dohme LLC, Rahway, NJ (US);

Werthenstein Biopharma GMBH, Lucerne, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 317/72 (2006.01); C07C 317/14 (2006.01);
U.S. Cl.
CPC ...
C07D 317/72 (2013.01); C07C 317/14 (2013.01); C07B 2200/13 (2013.01);
Abstract

The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2α inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.


Find Patent Forward Citations

Loading…